[GNI Group] Strengthening of the Representative Executive Officer System and Executive Appointments for Subsidiaries | May 2026

Strengthening of Executive Personnel and Management System

GNI Group is carrying out changes in the representative executive officer and executive personnel of its subsidiaries, advancing organizational structure to promote growth toward a global pharma. Ying Luo has been appointed as the new CEO of Gyre Therapeutics, accelerating the integration of clinical development capabilities and TPD technology within the group. This aims to drive new drug development and improve management responsiveness. Ryosei Matsui has been additionally appointed as Vice President, responsible for maintaining and operating the group's management, establishing a dual-leadership system.

Future Strategies and Enhancement of Corporate Value

These personnel changes are aimed at improving the group's mid- to long-term corporate value, strengthening information disclosure and collaboration in both Japanese and U.S. markets. Ying Luo will lead global strategies and new drug development, while Ryosei Matsui will oversee finance and operations, enabling rapid decision-making and stabilizing management response in a rapidly changing business environment.